ArticleJournal of computer-aided molecular design2026
Xanthine oxidase inhibitory potential of flavonoids from Pistacia integerrima: insights from molecular docking, MD simulations, SwissADME ADMET analysis and StopTox toxicity profile evaluation.
Article in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthesis, Characterization, In Vitro and In Silico Investigation of Azo-Based Co(III), Zn(II), and Pd(II) Complexes Against Human Leukemia.Chemistry & biodiversity · 2026Article
- A bivalent multi-epitope vaccine targeting CSP and TRAP of Plasmodium vivax designed through immunoinformatics and structural bioinformatics.BMC microbiology · 2026Article
- Clematis Chinensis Attenuates Hyperuricemia Through the Coordinated Regulation of Purine Metabolism and Inflammatory Responses: An Integrative Study.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Medicinal plants are an important source of bioactive secondary metabolites that are responsible for the development of new drugs. The main aim of this study was to explore Pistacia integerrima J. L. Stewart ex Brandis phytochemically and biologically explore P. integerrima. The defatted methanolic extract of P. integerrima galls was subjected to column chromatography, which yielded six flavonoids including 3,5,7,4/-tetrahydroxy-flavanone (1), naringenin (2), 3,5,4/-trihydroxy,7-methoxy-flavanone (3), sakuranetin (4), spinacetin (5), and patuletin (6). The defatted extract and the isolated compound (1-6) were assessed for in- vitro xanthine oxidase (XO). The samples to be tested were applied at a concentration of 0.5 mM and demonstrated a variable degree of XO inhibitory potential. The maximum inhibitory effect was observed for compound 6 (93.09%), followed by compounds 5 (89.02%) and 3 (87.92%). Six flavonoids from P. integerrima galls showed favorable drug-likeness, good gastrointestinal (GI) absorption (except for compound 6), and safe oral toxicity profiles. Docking and in vitro assays identified compounds 3, 5, and 6 as potent XO inhibitors that outperformed allopurinol. Density functional theory (DFT) analysis revealed that compound 3 was stable but less reactive, whereas compounds 5 and 6 were more reactive, with strong electrophilic properties. Furthermore, MD simulations confirmed the stable binding of these three compounds within the XO active site, with compound 6 demonstrating the highest interactions and structural stability. In conclusion, P. integerrima flavonoids, particularly compound 6, are significant XO inhibitors that may be used to treat hyperuricemia and hypoxic-ischemic encephalopathy (HIE).
Indexed as
Identifiers
41680586What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.